Table 1.
Baseline demographics and clinical characteristics of the ITT population
| Characteristic | Cisplatin + gemcitabine + axitinib (n = 38) |
|---|---|
| Age, years | |
| Mean (SD) | 60.5 (7.1) |
| Median (range) | 59.5 (47–73) |
| Gender | |
| Male | 34 (89.5) |
| Female | 4 (10.5) |
| Race | |
| White | 37 (97.4) |
| Black | 1 (2.6) |
| Smoking status | |
| Smoker | 33 (86.8) |
| Non-smoker | 5 (13.2) |
| Tumour histology | |
| Squamous cell carcinoma | 38 (100) |
| Disease stage | |
| IIIB | 5 (13.2) |
| IV | 33 (86.8) |
| ECOG performance status | |
| 0 | 12 (31.6) |
| 1 | 26 (68.4) |
| Prior surgery | 17 (44.7) |
| Bronchoscopy | 11 (28.9) |
| Lymph node/pleural biopsy | 6 (15.8) |
| Lobectomy | 2 (5.2) |
| Thoracic wall resection | 1 (2.6) |
Values are n (%) unless otherwise noted. ECOG, Eastern Cooperative Oncology Group; ITT, intent-to-treat; SD, standard deviation.